This Article Full Text Full Text (PDF) All Versions of this Article: 51/2/432    most recent HYPERTENSIONAHA.107.103267v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Savoia, C. Articles by Schiffrin, E. L. Search for Related Content PubMed PubMed Citation Articles by Savoia, C. Articles by Schiffrin, E. L. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ATENOLOL SPIRONOLACTONE Medline Plus Health Information High Blood Pressure

(Hypertension. 2008;51:432.)
© 2008 American Heart Association, Inc.

Original Articles Part 2

Selective Mineralocorticoid Receptor Blocker Eplerenone Reduces Resistance Artery Stiffness in Hypertensive Patients

From the Lady Davis Institute for Medical Research (C.S., F.A., E.L.S.), Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada; Division of Cardiology (C.S.), II Faculty of Medicine, University of Rome Sapienza and San Pietro Fatebenefratelli Hospital Research Center, Rome, Italy; and the Kidney Research Centre (R.M.T.), Ottawa Health Research Institute, University of Ottawa, Ottawa, Ontario, Canada.

Correspondence to Ernesto L. Schiffrin, Department of Medicine, SMBD-Jewish General Hospital, #B-127, 3755 Cote Ste-Catherine Rd, Montreal, Quebec, Canada H3T 1E2. E-mail ernesto.schiffrin{at}mcgill.ca

Some antihypertensive agents may improve resistance artery remodeling in hypertensive patients whereas other agents may not, for similar blood pressure reduction. We questioned whether the selective mineralocorticoid receptor blocker eplerenone improves resistance artery remodeling in hypertensive patients versus the β-blocker atenolol. Sixteen hypertensive patients were randomly assigned to double-blind daily treatment with eplerenone or atenolol. Resistance arteries from gluteal subcutaneous tissue were assessed on a pressurized myograph. After 1 year of treatment, systolic and diastolic blood pressures were similarly well controlled in both groups. Endothelial function did not change with treatment in either group. Media/lumen ratio and cross-sectional area were unchanged in either the atenolol or the eplerenone group. In atenolol-treated patients, the arterial wall became stiffer, whereas in the eplerenone-treated patients, it became less stiff and similar to that of a normotensive control group. The media collagen/elastin ratio was reduced only after eplerenone treatment. Circulating concentrations of osteopontin, monocyte chemoattractant protein-1, basic fibroblast growth factor, interleukin-8, and interleukin-10 were significantly reduced only by eplerenone. However, plasma interleukin-1 receptor a concentration was significantly reduced by both drugs. In conclusion, in hypertensive patients, blood pressure control for 1 year with atenolol was associated with increased wall stiffness of resistance arteries, whereas eplerenone treatment was associated with reduced stiffness, decreased collagen/elastin ratio, and a reduction in circulating inflammatory mediators. These data raise the possibility that eplerenone treatment of hypertensive patients when normalizing blood pressure could potentially be associated with better vascular protection and outcomes than the β-blocker atenolol, which remains to be demonstrated.

Key Words: aldosterone • vascular remodeling • extracellular matrix • collagen • elastin • inflammatory biomarkers